{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acral+Lentiginous+Melanoma&page=2", "query": { "condition": "Acral Lentiginous Melanoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acral+Lentiginous+Melanoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:34:25.996Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT00577382", "title": "SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Lentiginous Melanoma", "Acral Lentiginous Malignant Melanoma" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 5, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577382" }, { "nct_id": "NCT00700882", "title": "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2009-07-02", "completion_date": "2020-12-28", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 153, "location_summary": "Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700882" }, { "nct_id": "NCT00788775", "title": "Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Lentiginous Melanoma", "Acral Melanoma", "Melanoma" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-01-23", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 8, "location_summary": "Santa Monica, California • Aurora, Colorado • Tampa, Florida + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788775" }, { "nct_id": "NCT00470470", "title": "Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Malignant Melanoma", "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 8, "location_summary": "Los Angeles, California • Miami Beach, Florida • West Palm Beach, Florida + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470470" }, { "nct_id": "NCT00937937", "title": "Dinaciclib in Treating Patients With Stage IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Cutaneous Nodular Melanoma", "Lentigo Maligna Melanoma", "Low-CSD Melanoma", "Mucosal Melanoma", "Recurrent Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Dinaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2009-07-01", "completion_date": "2027-03-19", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 190, "location_summary": "Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 126 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00937937" }, { "nct_id": "NCT05549297", "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" }, { "name": "Tebentafusp with Pembrolizumab", "type": "DRUG" }, { "name": "Investigators Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2022-12-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549297" }, { "nct_id": "NCT05628883", "title": "Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Unresectable Melanoma", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "Ocular Melanoma", "Uveal Melanoma", "Iris Melanoma", "Conjunctival Melanoma", "Non-Cutaneous Melanoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2022-11-22", "completion_date": "2025-03-06", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05628883" }, { "nct_id": "NCT03025256", "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acral Lentiginous Melanoma", "Central Nervous System Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Leptomeningeal Neoplasm", "Melanocytoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Uveal Melanoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2018-05-02", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T23:34:25.996Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03025256" } ] }